Astrazeneca annual gross margin
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Astrazeneca Gross Margin Growth & History (AZN)
Astrazeneca's gross margin was 81.90% for fiscal 2025.
View full Astrazeneca company overviewAstrazeneca annual gross margin history
| Fiscal year | Period ended | Gross margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | 81.90% | +0.77 pp |
| 2024 | 2024-12-31 | 81.12% | −0.83 pp |
| 2023 | 2023-12-31 | 81.95% | +9.89 pp |
| 2022 | 2022-12-31 | 72.06% | +5.30 pp |
| 2021 | 2021-12-31 | 66.76% | −13.33 pp |
| 2020 | 2020-12-31 | 80.09% | +0.27 pp |
| 2019 | 2019-12-31 | 79.82% | +2.16 pp |
| 2018 | 2018-12-31 | 77.66% | −3.12 pp |
| 2017 | 2017-12-31 | 80.78% | −1.28 pp |
| 2016 | 2016-12-31 | 82.06% | +0.87 pp |
| 2015 | 2015-12-31 | 81.20% | — |
Astrazeneca quarterly gross margin
Q2.17
Q2.18
Q2.19
Q2.20
Q2.21
Q2.22
Q2.23
Q2.24
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Gross margin | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | 83.60% | +0.71 pp |
| Q1 2026 | 2026-03-31 | 82.48% | — |
| Q4 2025 | 2025-12-31 | 79.89% | — |
| Q3 2025 | 2025-09-30 | 81.56% | — |
| Q2 2025 | 2025-06-30 | 82.89% | −0.23 pp |
| Q2 2024 | 2024-06-30 | 83.13% | +0.30 pp |
| Q2 2023 | 2023-06-30 | 82.83% | +10.67 pp |
| Q2 2022 | 2022-06-30 | 72.17% | −1.18 pp |
| Q2 2021 | 2021-06-30 | 73.35% | −10.97 pp |
| Q2 2020 | 2020-06-30 | 84.32% | +2.57 pp |
| Q2 2019 | 2019-06-30 | 81.74% | +1.38 pp |
| Q2 2018 | 2018-06-30 | 80.37% | −0.82 pp |
| Q2 2017 | 2017-06-30 | 81.19% | — |
Astrazeneca gross margin trends
Over the last five fiscal years, Astrazeneca's gross margin increased from 80.09% to 81.90%, a change of +1.81 percentage points. The latest reported quarter, Q2 2026, shows 83.60%.
About the metric
What gross margin means
Gross margin measures the percentage of revenue remaining after the direct costs of producing goods or services. It helps show how efficiently a company turns sales into gross profit before operating expenses.
Calculation and source
How gross margin is calculated
TickerStat calculates gross margin as SEC-reported gross profit divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Astrazeneca source filings ↗Community posts
AstraZeneca receives priority review for perioperative bladder-cancer regimen
The FDA granted priority review to a regimen combining AstraZeneca ($AZN)’s Imfinzi with enfortumab vedotin around surgery for muscle-invasive bladder cancer in patients ineligible for, or declining, cisplatin chemotherapy. Imfinzi is given ...
AstraZeneca’s Klygefa receives a positive EU recommendation
European medicines advisers recommended AstraZeneca ($AZN)’s Klygefa, or gefurulimab, as an add-on to standard treatment for adults with generalized myasthenia gravis who are positive for anti-acetylcholine receptor antibodies. The Alexion ...
Enhertu receives European recommendation for an earlier breast-cancer setting
European advisers recommended Enhertu for postoperative treatment of adults with HER2-positive breast cancer who still have invasive disease after preoperative taxane-based chemotherapy and HER2-directed treatment. The drug is jointly devel ...
AstraZeneca receives US accelerated approval for Etcamah in a defined breast-cancer setting
AstraZeneca announced US accelerated approval of Etcamah on 7 September 2026. Approved setting Camizestrant, combined with a CDK4/6 inhibitor, is approved for adults with HR-positive, HER2-negative locally advanced or metastatic breast canc ...
